Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant DDI Study with Oral Contraceptives
NCT03249402Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seltorexant in major depressive disorder (MDD) and Insomnia, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Trough Plasma Concentration and 1 more. Started Aug 2017; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT03249402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249402.